Overview

Captures the state of the science with twenty reviews that examine the latest in today’s antiviral drug discovery efforts. Presents the fundamental principles of antiviral agents and forecasts future possibilities. Investigates novel enzyme and protein inhibitors. Analyzes clinical aspects of viral infection with regard to treatment and toxicity. Examines known and potential targets at all stages of viral development. Serves as a resource for virologists, biochemists, pharmaceutical chemists, and other investigators. Covers a broad range of viruses, including HIV-1, HSV, and HCV. This title is published by the American Society of Microbiology Press and distributed by Taylor and Francis in rest of world territories.

Full Product Details

Author:   Robert L Lafemina
Publisher:   American Society for Microbiology
Imprint:   American Society for Microbiology
Dimensions:   Width: 22.00cm , Height: 2.40cm , Length: 28.30cm
Weight:   1.320kg
ISBN:  

9781555814397

ISBN 10:   1555814395
Pages:   412
Publication Date:   09 May 2009
Audience:   College/higher education ,  General/trade ,  Tertiary & Higher Education ,  General
Format:   Hardback
Publisher's Status:   Unknown
Availability:   In Print  
Limited stock is available. It will be ordered for you and shipped pending supplier's limited stock.

Table of Contents

Table of Contents 1. Antiherpesviral DNA Polymerase Inhibitors Donald M. Coen 2. Entry Inhibitors of Human Immunodeficiency Virus Masanori Baba 3. Human Immunodeficiency Virus Type 1 Non-Nucleoside Reverse Transcriptase Inhibitors Dirk Jochmans, Johan Vingerhoets, Eric Arnoult, Luc Geeraert, and Jerome Guillemont 4. Nucleoside Analogue Inhibitors of Human Immunodeficiency Virus Reverse Transcriptase Jerome Deval and Matthias Goette 5. Integrase as a Novel Target for the Inhibition of Human Immunodeficiency Virus Type 1 Infection: Current Status and Future Perspectives Linos P.R. Vandekerckhove, Frauke Christ, Zeger Debyser, Andrew Owen, David Back, Arnout Voet, Jonathan Schapiro, and Dirk Vogelaers 6. Human Immunodeficiency Virus Type 1 Tat and Rev as Potential Targets for Drug Development Sergei Nekhai and Kuan-Teh Jeang 7. Inhibitors of the Human Immunodeficiency Virus Protease Jorge L. Martinez-Cajas and Mark A. Wainberg 8. Hepatitis C Virus RNA-Dependent RNA Polymerase as a Target for Antiviral Drug Intervention: Non-Nucleoside Inhibitors Yaya Liu, Yupeng He, and Akhteruzzaman Molla 9. Nucleoside Analog Inhibitors of Hepatitis C Viral Replication Steven S. Carroll and Robert L. LaFemina 10. Antiviral Targets in Orthopoxviruses Mark N. Prichard and Earl R. Kern 11. Influenza Virus Antiviral Targets Gillian M. Air and Wayne J. Brouillette 12. Developments in the Search for Small Molecule Inhibitors for Treatment of Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV) Dale L. Barnard and Yohichi Kumaki 13. Antiviral Treatment of Flaviviruses Justin G. Julander 14. Clinical Aspects of Hepatitis C Virus Infection David Durantel and Fabien Zoulim 15. Microbicides: Molecular Strategies for Prevention of Sexually Transmitted Viral Disease Raina N. Fichorova 16. Phenotypic Susceptibility Assays for Human Immunodeficiency Virus Type 1 Neil T. Parkin, Eoin Coakley, and Christos J. Petropoulos 17. Metabolism of Antiviral Nucleosides and Nucleotides Adrian S. Ray and Michael J. M. Hitchcock 18. Targeting the Interferon Response for Antiviral Therapy Michael D. Robek 19. Toll-Like Receptors: Novel Molecular Targets for Antiviral Immunotherapy Raymund R. Razonable, Albert J. Eid, and Martin Henault 20. New Herpes Simplex Virus Replication Targets Sandra K. Weller Afterword: Closing Thoughts Robert L. LaFemina

Reviews

Author Information

Tab Content 6

Author Website:  

Countries Available

All regions